Skip to main content

6 Result(s)

within C. Massard Remove this filter

and
Your search also matched 16 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors

Include preview-only content

  1. Article

    Open Access

    Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

    High circulating tumor cell (CTC) counts are associated with poor prognosis in advanced prostate cancer, and recently CTC number was suggested to be a surrogate for survival in metastatic castrate-resistant pr...

    C. R. Lindsay, S. Le Moulec, F. Billiot, Y. Loriot, M. Ngo-Camus, P. Vielh… in BMC Cancer (2016)

    Download PDF (1199 KB) View Article

  2. Article

    Erratum: hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway

    Correction to: Oncogene (2006) 25, 4505–4514; doi:10.1038/sj.onc.1209487; published online 17 April 2006 Errors were inadvertently included in Figure 3a of the article mentioned above. In particular, represent...

    C Massard, Y Zermati, A-L Pauleau, N Larochette, D Métivier, L Sabatier… in Oncogene (2013)

    Download PDF (328 KB) View Article

  3. Article

    Open Access

    A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

    Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance o...

    F Farace, C Massard, N Vimond, F Drusch, N Jacques, F Billiot… in British Journal of Cancer (2011)

    Download PDF (303 KB) View Article

  4. Article

    Open Access

    A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

    Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients...

    E Boven, C Massard, J P Armand, C Tillier, V Hartog, N M Brega… in British Journal of Cancer (2010)

    Download PDF (407 KB) View Article

  5. Article

    Open Access

    Erratum: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

    Correction to: British Journal of Cancer (2008) 97, 857–861, doi:10.1038/sj.bjc.6603942 The authors of the above paper, first published in October 2007, would like to add the following acknowledgement to their...

    C Massard, J-J Voigt, A Laplanche, S Culine, A Lortholary… in British Journal of Cancer (2008)

    Download PDF (49 KB) View Article

  6. Article

    Open Access

    Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

    Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the exp...

    C Massard, J-J Voigt, A Laplanche, S Culine, A Lortholary… in British Journal of Cancer (2007)

    Download PDF (457 KB) View Article